{
    "nct_id": "NCT03211741",
    "official_title": "Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema",
    "criteria": {
        "raw_text": "Inclusion Criteria:\n\n1. Age ≥ 18 years of either gender\n2. Written informed consent must be obtained before any intravitreal injection of bevacizumab is performed\n3. Visual impairment predominantly due to abnormal new vessel ingrowth and/or macular edema. The presence of fluid (intraretinal, subretinal or sub-RPE) detected clinically or on the ocular coherence tomography.\n\nIf both eyes are eligible for the study, both eyes can be included in the study.\n\nExclusion Criteria:\n\n1. Women who are pregnant or breastfeeding (pregnancy defined as the state of a female after conception until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test (\\> 5mIU/mL)\n2. Women of child bearing potential must be practicing effective contraception implemented during the trial and for at least 28 days following the last dose of study medication\n3. Tromboembolic event (CVA or transient ischemic attack, AMI) less than 3 months prior to the intravitreal injection of bevacizumab\n4. History of hypersensitivity for bevacizumab.\n\nsex: ALL\n\nminimumAge: 18 Years\n\nstdAges: ['ADULT', 'OLDER_ADULT']",
        "inclusion": "1. Age ≥ 18 years of either gender\n2. Written informed consent must be obtained before any intravitreal injection of bevacizumab is performed\n3. Visual impairment predominantly due to abnormal new vessel ingrowth and/or macular edema. The presence of fluid (intraretinal, subretinal or sub-RPE) detected clinically or on the ocular coherence tomography.\n\nIf both eyes are eligible for the study, both eyes can be included in the study.",
        "exclusion": "1. Women who are pregnant or breastfeeding (pregnancy defined as the state of a female after conception until the termination of gestation, confirmed by a positive human chorionic gonadotropin laboratory test (> 5mIU/mL)\n2. Women of child bearing potential must be practicing effective contraception implemented during the trial and for at least 28 days following the last dose of study medication\n3. Tromboembolic event (CVA or transient ischemic attack, AMI) less than 3 months prior to the intravitreal injection of bevacizumab\n4. History of hypersensitivity for bevacizumab."
    }
}